ClinicalTrials.gg

Program

maralixibat

Also written as “Maralixibat”, “LUM001” and “LUM001 (Maralixibat)”.

Its studies are mostly in Alagille Syndrome · Cholestasis, progressive familial intrahepatic 1 · Cholangitis, Sclerosing · Liver Cirrhosis, Biliary · Intrahepatic Cholestasis of Pregnancy, led by 2 companies.

Furthest: phase 4, since Sep 17, 202521 company-led studies, 3 open or runningNext primary completion: Jan 12, 2029 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Mirum Pharmaceuticals193 open or runningphase 4since Sep 17, 2025Jul 16, 2013Jan 12, 2029phase 2 · NCT07823127
Takeda20 open or runningphase 3since Sep 14, 2022Sep 14, 2022none ahead

Also a collaborator on its studies: lumena-pharmaceuticals-inc.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

Before these, 6 studies since Jul 16, 2013.

  1. Apr 16, 2014Phase 2 study in Alagille SyndromeMirum Pharmaceuticals · NCT02117713 · 34 enrolled · United States, Canada
  2. Jun 9, 2014Phase 2 study in Alagille SyndromeMirum Pharmaceuticals · NCT02160782 · 31 enrolled · Australia, Belgium, France and more
  3. Dec 12, 2014Phase 2 study in Liver Cirrhosis, BiliaryMirum Pharmaceuticals · NCT02321306 · United States, United Kingdom
  4. Jun 10, 2015Phase 1 study in Healthy VolunteersMirum Pharmaceuticals · NCT02475317 · 84 enrolled · United States
  5. Nov 14, 2017Phase 3 study in Cholestasis, progressive familial intrahepatic 1Mirum Pharmaceuticals · NCT03353454
  6. Apr 1, 2019Phase 3 study in Cholestasis, progressive familial intrahepatic 1Mirum Pharmaceuticals · NCT03905330 · 93 enrolled · United States, Argentina, Austria and more
  7. Oct 1, 2019Phase 2 study in Bile Duct DiseasesMirum Pharmaceuticals · NCT04168385 · 52 enrolled · United States, Australia, Belgium and more
  8. Dec 2, 2019Phase 3 study in Cholestasis, progressive familial intrahepatic 1Mirum Pharmaceuticals · NCT04185363 · 84 enrolled · United States, Argentina, Austria and more
  9. Aug 20, 2020Phase 2 study in Biliary AtresiaMirum Pharmaceuticals · NCT04524390 · 75 enrolled · United States, China, Germany and more
  10. Jan 25, 2021Phase 2 study in Cholestasis, progressive familial intrahepatic 1Mirum Pharmaceuticals · NCT04729751 · 27 enrolled · United States, Belgium, Brazil and more
  11. Sep 14, 2022Takeda's first studies: 2 phase 3 studiesNew to TakedaTakeda · NCT05543187, NCT05543174
  12. Aug 8, 2024Phase 3 study in Cholangitis, SclerosingMirum Pharmaceuticals · NCT06553768 · 90 enrolled · United States, Brazil, Canada and more
  13. Sep 17, 2025Phase 4 study in Alagille SyndromeMirum Pharmaceuticals · NCT07290257 · 230 planned · Belgium, France, Germany and more
  14. Aug 12, 2026Phase 2 study in Intrahepatic Cholestasis of PregnancyMirum Pharmaceuticals · NCT07823127 · 15 planned

Ahead

  1. Jan 12, 2029Primary completion: phase 2 study in Intrahepatic Cholestasis of PregnancyMirum Pharmaceuticals · NCT07823127
  2. Sep 22, 2030Primary completion: phase 4 study in Alagille SyndromeMirum Pharmaceuticals · NCT07290257

TargetBeta

SLC10A2 →read by rule
“Ileal bile acid transporter inhibitor; Ileal bile acid transporter inhibitor”ChEMBL 37, by rule

Other programs on SLC10A2

ProgramCompanyFurthest phaseStudies
linerixibatruleGlaxoSmithKlinephase 314

Studies

All 21 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusLed byPrimary completionSize
NCT07823127Intrahepatic Cholestasis of Pregnancy2Not yet recruitingMirum PharmaceuticalsJan 12, 202915
NCT07290257Alagille Syndrome · Belgium, France, Germany and more4RecruitingMirum PharmaceuticalsSep 22, 2030230
NCT06553768Cholangitis, Sclerosing · United States, Brazil, Canada and more3Active, not recruitingMirum PharmaceuticalsJul 29, 202690
NCT05543187Cholestasis, progressive familial intrahepatic 1 · Japan3CompletedTakedaSep 4, 20235
NCT05543174Alagille Syndrome · Japan3CompletedTakedaOct 25, 20237
NCT04729751Cholestasis, progressive familial intrahepatic 1 · United States, Belgium, Brazil and more2CompletedMirum PharmaceuticalsDec 17, 202427
NCT04524390Biliary Atresia · United States, China, Germany and more2CompletedMirum PharmaceuticalsNov 7, 202375
NCT04185363Cholestasis, progressive familial intrahepatic 1 · United States, Argentina, Austria and more3CompletedMirum PharmaceuticalsApr 23, 202584
NCT04168385Bile Duct Diseases · United States, Australia, Belgium and more2CompletedMirum PharmaceuticalsSep 4, 202452
NCT03905330Cholestasis, progressive familial intrahepatic 1 · United States, Argentina, Austria and more3CompletedMirum PharmaceuticalsSep 1, 202293
NCT03353454Cholestasis, progressive familial intrahepatic 13WithdrawnMirum PharmaceuticalsJun 15, 20200
NCT02475317Healthy Volunteers · United States1CompletedMirum PharmaceuticalsDec 1, 201584
NCT02321306Liver Cirrhosis, Biliary · United States, United Kingdom2WithdrawnMirum PharmaceuticalsDec 20170
NCT02160782Alagille Syndrome · Australia, Belgium, France and more2CompletedMirum PharmaceuticalsMay 28, 202031
NCT02117713Alagille Syndrome · United States, Canada2CompletedMirum PharmaceuticalsJun 1, 202034
NCT02061540Cholangitis, Sclerosing · United States, Canada, United Kingdom2CompletedMirum PharmaceuticalsFeb 201627
NCT02057718Cholestasis, progressive familial intrahepatic 1 · United States, France, Poland and more2CompletedMirum PharmaceuticalsMay 8, 202033
NCT02057692Alagille Syndrome · United States, Canada2CompletedMirum PharmaceuticalsNov 16, 201637
NCT02047318Alagille Syndrome · United Kingdom2CompletedMirum PharmaceuticalsJun 17, 202019
NCT01904058Liver Cirrhosis, Biliary · United States, Canada, United Kingdom2CompletedMirum PharmaceuticalsApr 201566
NCT01903460Alagille Syndrome · United Kingdom2CompletedMirum PharmaceuticalsFeb 201520

How it is read

Names in the registry

  • “Maralixibat”, 9 entries
  • “LUM001”, 5 entries
  • “LUM001 (Maralixibat)”, 4 entries
  • “TAK-625”, 2 entries
  • “Livmarli Oral Product”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.